Zenas BioPharma, Inc. - 10-Q Filing
Zenas BioPharma filed its Q1 2026 10-Q to disclose financial and operational updates, including a $2.5 billion convertible senior notes offering due in 2032, an equity offering, and agreements with partners such as Innocare Pharma Inc., Bristol-Myers Squibb, and Xencor Inc.
Tickers: $ZBIO